Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAAT3 | P53816 | 1/20 | 0.58 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.58 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.58 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MLYCD | O95822 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14100869 | 0.87 | ESRRG (0.61) | CNR1EPHX2 | |
| SCHEMBL4179064 | 0.84 | HPGD (0.57) | PLAAT3PLAAT5PLAAT2PLAAT4CNR1 | |
| SCHEMBL6433557 | 0.84 | KDM4E (0.61) | PLAAT3PLAAT5PLAAT2PLAAT4MEN1 | |
| SCHEMBL2771700 | 0.84 | PLAAT3 (0.64) | PLAAT3PLAAT5PLAAT2PLAAT4CNR1 | |
| SCHEMBL4702861 | 0.83 | ALDH1A1 (0.47) | PLAAT3PLAAT5PLAAT2PLAAT4HDAC1 | |
| SCHEMBL14141265 | 0.83 | NPC1 (0.59) | PLAAT3PLAAT5PLAAT2PLAAT4CNR1 | |
| SCHEMBL1094537 | 0.83 | CNR1 (0.57) | PLAAT3PLAAT5PLAAT2PLAAT4CNR1 | |
| SCHEMBL419646 | 0.83 | CNR1 (0.50) | PLAAT3PLAAT5PLAAT2PLAAT4CNR1 | |
| SCHEMBL4700346 | 0.83 | ESRRG (0.54) | MEN1KMT2AMLYCDALDH1A1POLB | |
| SCHEMBL6275214 | 0.83 | SMN1; SMN2 (0.47) | PLAAT3PLAAT5PLAAT2PLAAT4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112457245-B | Synthesis method of 7- (trifluoromethyl) isoquinoline-5-amine | 苏州康润医药有限公司 | 2022-11-22 | — | — | CN | claimed |
| WO-2019044940-A1 | CYCLIC AMINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | 東レ株式会社 | 2019-03-07 | — | — | WO | disclosed |
| US-7700772-B2 | Amino heterocyclic modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700772-B2 | Amino heterocyclic modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7557120-B2 | Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557120-B2 | Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557124-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557124-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7166614-B2 | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166614-B2 | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20070004714-A1 | Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004714-A1 | Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20050267146-A1 | 3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2005-12-01 | — | — | US | disclosed |
| US-6602867-B1 | Triazole compounds with dopamine-D3-receptor affinity | ABBOTT LABORATORIES | 2003-08-05 | — | — | US | disclosed |
| EP-0917530-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2003-02-19 | — | — | EP | disclosed |
| US-6046210-A | ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-04-04 | — | — | US | disclosed |
| EP-0917530-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-26 | — | — | EP | disclosed |
| WO-1997043262-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267146-A1 | 3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | CCR5, CXCR3, CCR2 | PLAAT3 534/4885PLAAT5 1255/4885PLAAT2 1380/4885 |
| US-20070004714-A1 | Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity | CCR2, CCR1, CCR8 | PLAAT3 3547/4885PLAAT5 3517/4885PLAAT2 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.